Drug Trial Radar · NCT06189391
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 16, 2021
Primary completion
Sep 30, 2028
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- MSD R&D (China) Co., Ltd.Merck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment. MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about: * The safety of MK-1045 and how well people tolerate it. * The highest dose of MK-1045 that is well tolerated. * How well MK-1045 works to treat relapsed or refractory B-NHL.
Conditions
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
MK-1045Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experience a Dose-limiting Toxicity (DLT)Time frame: Up to ~28 Days
- Number of Participants who Experience an Adverse Event (AE)Time frame: Up to ~15 months
- Number of Participants who Experience a Serious Adverse Events (SAE)Time frame: Up to ~15 months
- Number of Participants who Experience a Drug-related Adverse Event (DRAE)Time frame: Up to ~15 months
- Number of Participants who Experience an AE of Grade 3 or higherTime frame: Up to ~15 months
- Number of Participants who Experience an AE for Each Severity Grade from 1-5Time frame: Up to ~15 months
- Number of Participants who Experience a SAE or Serious Drug-related AETime frame: Up to ~15 months
- Number of Participants who Experience a Dose Modification Due to an AE or DRAETime frame: Up to ~15 months
- Number of Participants who Withdraw from the Study due to an AE or DRAETime frame: Up to ~15 months
- Number of Participants who Died due to an AE or DRAETime frame: Up to ~15 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Fifth Medical Center of PLA General Hospital ( Site 0005)
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer hospital ( Site 0001)
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University ( Site 0011)
Xiameng, Fujian, China · Recruiting
Sun Yat-Sen University Cancer Center ( Site 0003)
Guangzhou, Guangdong, China · Recruiting
The Fourth Hospital of Hebei Medical University. ( Site 0004)
Shijiazhuang, Hebei, China · Recruiting
Henan Cancer Hospital ( Site 0009)
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University ( Site 0006)
Zhengzhou, Henan, China · Recruiting
Jiangxi Cancer Hospital ( Site 0007)
Nanchang, Jiangxi, China · Recruiting
The First Hospital Of Jilin University ( Site 0014)
Changchun, Jilin, China · Recruiting
Shandong Cancer Hospital ( Site 0008)
Jinan, Shandong, China · Active not recruiting
Fudan University Shanghai Cancer Center ( Site 0012)
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital,Fudan University ( Site 0013)
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai East Hospital ( Site 0002)
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Cancer Hospital. ( Site 0018)
Chengdu, Sichuan, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital ( Site 0010)
Tianjinc, Tianjin Municipality, China · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.